The CNS and gut peptide Neuromedin U (NMU) inhibits feeding following intracerebroventricular injection. This study aimed to explore the hypothalamic actions of NMU on feeding and the hypothalamo-pituitary-adrenal (HPA) axis. Intra-paraventricular nucleus (PVN) NMU dose-dependently inhibited food intake with a minimum effective dose of 0.1nmol and a robust effect at 0.3nmol. Feeding inhibition was mapped by NMU injection into 8 hypothalamic areas. NMU (0.3nmol) inhibited food intake in the PVN (0-1h: 59 ± 6.9% control; p<0.001) and arcuate nucleus (0-1h: 76 ± 10.4% control; p<0.05). Intra-PVN NMU markedly increased grooming and locomotor behavior and dose-dependently increased plasma ACTH (NMU 0.3nmol: 24.8 ± 1.9 vs. saline 11.4 ± 1.0 pg/ml, p<0.001) and corticosterone (NMU 0.3nmol: 275.4 ± 40.5 ng/ml vs. saline 129.4 ± 25.0 ng/ml, p<0.01).
Introduction
Neuromedin U (NMU) was first isolated from porcine spinal cord in 1985 and named for its potent contractile activity on the uterus (1) . Two molecular forms were purified; an octapeptide (NMU-8) and the N-terminally extended 25 amino acid form (NMU-25) (1).
Both forms are biologically active, stimulating contraction of rat uterus in vitro and causing potent vasoconstriction in rats and dogs. (1) (2) (3) . Neuromedin U has since been fully sequenced in several species including dog (4), rabbit (5), frog (6) and human (7) . In rat a 23 amino acid peptide, NMU-23, is the naturally occurring form (8;9) . The C-terminal region of NMU is highly conserved between species. Neuromedin U-like immunoreactivity (NMU-LI) is found in spinal cord, several brain regions including the hypothalamus, nerves throughout the gastrointestinal tract, the urogenital tract and the pituitary and thyroid glands (1;10-14) . The direct actions of NMU on the uterus, gut and vascular smooth muscle have been investigated (1) (2) (3) . However, despite the fact that NMU is an abundant hypothalamic peptide (14) , a possible role for hypothalamic NMU is only just being explored.
NMU-LI and mRNA expression are abundant in the central nervous system (CNS), particularly in nuclei of the brain stem and hypothalamus (13;15) . Within the hypothalamus NMU-immunoreactive cell bodies and mRNA expression are restricted to the arcuate nucleus (Arc) and median eminence (ME) (13;15) . The paraventricular nucleus (PVN), ventromedial nucleus (VMN), dorsomedial nucleus (DMN) and Arc receive dense innervation by NMUimmunoreactive fibers (13) . This pattern of neuronal location and projection is similar to that of other neural networks thought to regulate food intake and body weight (16) . It has recently been shown that ICV administration of NMU inhibits food intake and that hypothalamic NMU mRNA expression is reduced by fasting and in the leptin-deficient ob/ob mouse (15) , suggesting that hypothalamic NMU may play a role in appetite inhibition. An aim of these studies was to further characterize the anorectic effect of NMU and its regulation by leptin.
Two G-protein coupled receptors, termed NMU1R and NMU2R, have been identified with a high affinity for NMU (15;17-20) . The NMU1R has a wide distribution in peripheral tissues including the gastrointestinal tract and adrenal cortex, but is not found in the CNS (15) . The NMU2R is found in a number of peripheral tissues but is also expressed in discrete CNS sites in rat and human (15) . Despite the fact that several hypothalamic nuclei, as described above, receive NMU projections, the only identified hypothalamic site of NMU2R expression is the PVN (15;21). The PVN is important in the hypothalamic control of food intake (16) . Many peptides known to alter food intake influence feeding most potently in this nucleus (22) (23) (24) . It is also a key nucleus in the control of the hypothalamo-pituitary-adrenal (HPA) axis, being the site of corticotrophin releasing hormone (CRH) and arginine vasopressin (AVP) synthesis (25;26) .
Several observations suggest that NMU is linked to the HPA axis. In the pituitary, NMU-LI is found in the majority of corticotrophs (27;28) . Also, NMU may act directly on the adrenal gland. In vitro, NMU stimulates synthesis of steroids by adrenal slices, via a mechanism dependent upon the presence of medullary chromaffin cells (29) . In vivo, NMU increases plasma corticosterone and the volume of the zona fasiculata following subcutaneous administration for 6 days in rats (30) . It is not known whether NMU has a hypothalamic action on release of CRH or AVP and hence plasma concentration of adrenocorticotrophic hormone (ACTH) and adrenal steroids.
The current study aimed to investigate the effect of NMU on the HPA axis at the hypothalamic level in vivo, by measuring the plasma ACTH and corticosterone response to NMU following direct administration into the PVN. In order to explore the hypothalamic mechanism of action, the effect of NMU on release of CRH and AVP from hypothalamic explants in vitro was investigated. Although the only confirmed hypothalamic site of NMU receptor expression is the PVN (15) , NMU fibers project to several other hypothalamic nuclei (13) . We aimed to localize the hypothalamic site of action of NMU on food intake by using microinjection into the hypothalamic sites which receive NMU-immunoreactive neuronal projections. We also aimed to investigate whether ICV or intranuclear administration of NMU was associated with any changes in behavior other than feeding. Hypothalamic explants in vitro were used to examine the effect of leptin on NMU release. In this way we aimed to explore the site and mechanisms of the hypothalamic actions of NMU in regulation of food intake, behavior and the HPA axis.
Materials and Methods
Experimental Animals Male Wistar rats (Imperial College, London, UK) weighing 200-300g were maintained in individual cages (cannulated rats) or in cages of 5 (rats for in vitro experiments) under controlled temperature (21-23C) and light (12h light/dark cycle, lights on at 07.00h) with ad libitum access to food (RM1 diet, SDS UK Ltd.) and water. All animal experimentation was conducted in accordance with accepted standards of humane animal care.
Materials
Full length rat NMU (NMU-23) was custom synthesized (IAF Biochem, Quebec, Ontario, Canada) and used in all in vitro and in vivo experiments. Leptin was purchased from R&D (Minneapolis, USA). Reagents for basal hypothalamic explant experiments were supplied by BDH (Poole, Dorset, UK).
ICV and intranuclear cannulation and injections
Animal surgical procedures and handling were carried out as previously described (24;31). were excluded due to cannula misplacement.
Static Incubation of hypothalamic explants.
Static incubation of hypothalamic explants was performed as previously described (33) . Male (14), Arc (14), VMN (14) .
Investigation of the effect of intra-PVN microinjection of NMU on behavior.
Following an overnight fast, a separate group of rats (n=6 per group), cannulated into the PVN, were injected in the early light phase with saline or NMU 0.3nmol and behavior was observed as described above.
Investigation of the effect of NMU on the HPA axis.
A separate group of PVN cannulated rats were injected in the early light phase (09.00- 
Radioimmunoassays
ACTH was measured using a solid-phase immuno-radiometric assay (Euro-Diagnostica, Arnhem, the Netherlands). Plasma corticosterone was measured using a commercially available radioimmunoassay (RIA) kit (ICN Biomedicals inc, USA). CRH, AVP and NMU were measured using RIAs developed in the department and described previously elsewhere (10;38;39). Briefly, CRH-like immunoreactivity (CRH-LI) was measured using an antibody raised in a rabbit immunized with synthetic CRH 41 conjugated to bovine serum albumin (BSA) by glutaraldehyde and used at a final dilution of 1:380000. followed by centrifugation at 2500 r.p.m. Assay sensitivities were 2fmol/tube for CRH, 0.5fmol/tube for AVP and 6fmol/tube for NMU (at 95% confidence limits). The inter-and intra-assay coefficients of variation were less than 10% for CRH and AVP and 13 and 9% respectively for NMU. The antibody used for AVP assay showed 50% cross-reactivity on a molar basis with lysine-vasopressin. Other than this the antibodies used did not cross react with any known hypothalamic peptides.
Statistics
Paired Student's t test was used for comparison of peptide release from hypothalamic explants in the basal and stimulated periods and between saline and NMU treatment in the intranuclear cross-over study. Unpaired Student's t test was used for comparison of food intake between rats receiving saline or NMU 1nnol ICV. One-way analysis of variance with post-hoc Tukey's test was used for comparison of the effects on food intake and the HPA axis of intra-PVN administration of multiple doses of NMU to saline control. As behavioral observation data were not normally distributed, Kruskall-Wallis test was used for comparisons between treatment groups.
Results

Investigation of the effect of ICV NMU on food intake.
In fasted rats, NMU (1nmol) significantly inhibited food intake in the first hour following ICV injection (3.8 ± 0.4g vs. saline control 5.4 ± 0.6g, p <0.05). There was no significant difference in food intake between NMU and saline treatment groups at any subsequent time interval between 1 and 24 hours post-injection.
Investigation of the effect of NMU on food intake following micro-injection into specific hypothalamic nuclei.
Injection of NMU (0.03, 0.1, 0.3 or 1.0nmol) into the hypothalamic PVN resulted in dose dependent inhibition of food intake (figure 2a). The lowest effective dose was 0.1nmol (0-1h food intake 6.4 ± 0.3g vs. saline control 8.2 ± 0.4g, p<0.05) with a robust effect at 0.3nmol (0-1h food intake 5.8 ± 0.5g, p<0.01 vs. saline control).
To localize the hypothalamic site of the anorectic action of NMU, saline and NMU were injected into specific hypothalamic nuclei of fasted rats, in a randomized cross-over study design. As these are paired observations, results are expressed as percentage of saline control.
NMU caused inhibition of feeding at 1 hour following injection into the PVN (59 ± 6.9% control; p<0.001, figure 2b ). Inhibition of 0-1h food intake was also seen after intra-arcuate NMU administration (76 ± 10.4% control; p<0.05, figure 2b ). No immediate inhibition of feeding was seen following injection of NMU into any of the other hypothalamic areas ( figure   2b ).
Cumulative food intake following intra-PVN injection of NMU remained suppressed at 2, 4 and 24 hours (figure 3a), however this was accounted for by the marked suppression of food intake in the first hour post-injection. Following intra-arcuate NMU administration, cumulative food intake after 1 hour was not significantly different from saline-treated controls (figure 3b). A delayed suppression of cumulative food intake was noted following administration of NMU into the MPO (figure 3c). This was accounted for by reduced food consumption between 4 and 8 hours post-injection (4.3 ± 0.7g vs saline 6.8 ± 0.6g, p<0.05) and during the dark phase between 8 and 24 hours post-injection (12.5 ± 1.5g vs saline 17.9 ± 1.1g, p<0.05).
Investigation of the effect of ICV and intra-PVN administration of NMU on behavior.
The number of observations of each defined behavior was calculated and expressed as a Despite the reduction in quantity of food eaten, there was no significant reduction in the observed number of feeding episodes in NMU-treated rats compared to saline-treated rats (figure 4). All behaviors observed were readily assigned to the pre-defined treatment categories and no adverse behaviors were observed in either treatment group. 
Investigation
Investigation of NMU release from and NMU effect on hypothalamic explants in vitro.
As a putative hypothalamic satiety signal we hypothesized that NMU release from its hypothalamic site of synthesis in the arcuate nucleus may be regulated by the peripheral satiety signal leptin. Leptin (100nM) significantly stimulated release of NMU from medial basal hypothalamic explants in vitro (figure 6a: 141.9 ± 20.4 fmol/explant vs basal release of 92.9 ± 9.4 fmol/explant, n=36; p<0.01).
Hypothalamic explants were used to investigate whether stimulation of the HPA axis by NMU may be via release of CRH and/or AVP. NMU (10, 100 and 1000nM) significantly stimulated release of CRH from medial basal hypothalamic explants in vitro (figure 6b, NMU 100nM 5.9 ± 0.92 pmol/explant vs basal release of 3.8 ± 0.39 pmol/explant, n = 29; p<0.01).
Similarly, NMU (10 and 100nM) stimulated AVP release (figure 6c, NMU 100nM 124.5 ± 21.8 fmol/explant vs basal release of 74.5 ± 7.6 fmol/explant, n = 30; p<0.01)
Discussion
The current study adds to the accumulating body of evidence that NMU acts at the hypothalamic level to inhibit food intake (15; 20) . NMU may be a physiological regulator of feeding and body weight, as NMU-specific antibodies have been demonstrated to stimulate feeding (20) . Howard and co-workers first demonstrated that NMU inhibited food intake following ICV administration, but did not cause conditioned taste aversion (15) . They further demonstrated that hypothalamic NMU expression was reduced in rats following a 48-hour fast and in leptin-deficient ob/ob mice when compared to wild-type littermates (15) . We confirm that NMU inhibits food intake following ICV administration.
In the current study we have administered NMU into discrete hypothalamic areas, to investigate whether the feeding inhibition can be localized to specific hypothalamic nuclei. It is unlikely that the effect on food intake in the MPO is due to diffusion of peptide to the PVN, as no effect is seen until 4 hours. Also, no similar effect was seen after injection of nuclei much closer to the PVN, such as the AHA. It is possible that this delayed effect is indirect, involving the activation or inhibition of other neuronal regulatory systems.
As NMU is a putative anorectic neurotransmitter, we investigated the effect of leptin on NMU release from hypothalamic explants. Leptin stimulated NMU release in this system. Others have shown that in the presence of low or absent circulating leptin (in fasting rats and in leptin deficient ob/ob mice) hypothalamic NMU expression is reduced (15) . These data, taken together, suggest that NMU release may be stimulated by leptin and NMU synthesis inhibited in its absence.
The behavioral changes observed after administration of NMU, either ICV or into the PVN, were more striking than the inhibition of food intake. Others have reported similar behavioral changes in response to ICV NMU (42) . It has been postulated that NMU caused locomotor and grooming behaviors via CRH neurons in the PVN, as the behavior pattern was similar to the stress response induced by ICV CRH (43) (44) (45) . Furthermore, the locomotor and grooming response to NMU was attenuated by the CRH antagonist alpha-helical CRH or by anti-CRH IgG (42) . The locomotor response to NMU was also absent in CRH knockout mice (42) . However CRH neurons involved in the stress response are also located in the central nucleus of the amygdala as well as the hypothalamic PVN (46 (45) . Therefore, hypothalamic NMU has similar effects on feeding and stressrelated behaviors to CRH and appears to mediate these actions via the PVN, at least in part through CRH release. We hypothesized that in addition to stimulating CRH neurons involved in arousal and stress-related behaviors, NMU may also stimulate the hypophysiotrophic CRH/AVP neurons responsible for activation of the HPA axis. NMU administration into the PVN resulted in increased plasma ACTH and corticosterone at 20 minutes post-injection. In combination with the finding that NMU increased release of CRH and AVP from hypothalamic explants in vitro, this suggests that CRH/AVP neurons projecting to the median eminence are NMU-responsive. This is the first report that NMU stimulates the HPA axis at the hypothalamic level.
The lowest effective doses of NMU in the in vivo and in vitro experiments were greater than the amount of NMU released from medial basal hypothalamic explants in vitro. However, due to peptide degradation and the requirement for tissue penetration, the actual concentration of NMU reaching the NMUR on NMU-responsive neurons, both after ICV and intranuclear administration in vivo and after application to hypothalamic explants in vitro, will be less than the initial concentration administered. Within the hypothalamus NMU appears to be restricted to a small sub-group of neurons with cell bodies in the Arc and median eminence (13;15) and with projections to several nuclei, particularly the PVN, VMN, DMN and Arc (13) . Whilst the total amount of NMU released from a hypothalamic explant in vitro may be relatively small, the concentration of NMU achieved in the synaptic cleft between NMU neurons and NMU target neurons is likely to be much higher. It is possible that the concentration of NMU occurring physiologically at the NMUR of NMU-responsive neurons is comparable to that achieved after administration of effective doses of NMU in vivo and in vitro. At present, this remains speculative and the physiological significance of the actions of NMU described above remains to be established.
In summary we present data to suggest that NMU inhibits food intake, via an action on the hypothalamic PVN and Arc. Hypothalamic NMU release is stimulated by leptin, as would be expected for a putative satiety signal. NMU inhibits feeding and stimulates stress-related behaviors and the HPA axis via an action on the PVN which appears to involve CRH release. 
